



Markets
/
Stocks
/
nasdaq-amgn
/

Amgen Inc

AMGN

View Detailed Chart

280.840USD

+1.000+0.36%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

150.78BMarket Cap

36.87P/E TTM



Amgen Inc

280.840

+1.000+0.36%

Company

Intraday

30m

Today

+0.36%

5 Days

+1.28%

1 Month

-8.14%

6 Months

-11.40%

Year to Date

+7.75%

1 Year

+4.02%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 33 analysts

BUY

Current Rating

320.363

Target Price

14.07%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

Amgen Inc

AMGN

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Gilead Sciences Inc

GILD

BioMarin Pharmaceutical Inc

BMRN

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(4)

Buy(1)

Indicators

Sell(2)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.579

Sell

RSI(14)

41.057

Neutral

STOCH(KDJ)(9,3,3)

41.059

Neutral

ATR(14)

11.728

Low Volatility

CCI(14)

-37.865

Neutral

Williams %R

54.502

Neutral

TRIX(12,20)

-0.435

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

278.132

Buy

MA10

282.579

Sell

MA20

290.180

Sell

MA50

302.161

Sell

MA100

288.288

Sell

MA200

304.784

Sell

News

Bernstein cuts Amgen PT on uncertainty over obesity drug candidate MariTide

** Bernstein cuts PT on drugmaker Amgen AMGN.O to $350 from $380, citing uncertainty over co's key obesity drug candidate MariTide** New PT is nearly a 19% upside to stock's last close** Brokerage says MariTide is a higher-risk-and-high-reward opportunity** Adds obesity pipeline is advancing...

ReutersThu, Feb 20

Amgen profits rise, next MariTide studies start by mid-year

Feb 4 (Reuters) - Amgen AMGN.O posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

ReutersTue, Feb 4

Company

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Company codeAMGN

CompanyAmgen Inc

CEOMr. Robert A. (Bob) Bradway

Websitehttps://www.amgen.com/